context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the $ 27 million of aggregate principal payme... | text | 27 | monetaryItemType | text: <entity> 27 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and... | us-gaap:DebtInstrumentPeriodicPaymentPrincipal |
During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the $ 27 million of aggregate principal payme... | text | 90 | monetaryItemType | text: <entity> 90 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and... | us-gaap:DebtInstrumentPeriodicPaymentPrincipal |
During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the $ 27 million of aggregate principal payme... | text | 5 | monetaryItemType | text: <entity> 5 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and ... | us-gaap:DebtInstrumentPeriodicPaymentPrincipal |
During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the $ 27 million of aggregate principal payme... | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and... | us-gaap:DebtInstrumentPeriodicPaymentPrincipal |
During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and discontinued operations). Included in the $ 27 million of aggregate principal payme... | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company made aggregate principal repayments of mortgage debt of $ 27 million, $ 90 million, and $ 5 million, respectively (excluding mortgage debt on assets held for sale and... | us-gaap:NumberOfRealEstateProperties |
December 31, 2023 was an $ 85 million | text | 85 | monetaryItemType | text: <entity> 85 </entity> <entity type> monetaryItemType </entity type> <context> December 31, 2023 was an $ 85 million </context> | us-gaap:DebtInstrumentFaceAmount |
The Company has $ 142 million | text | 142 | monetaryItemType | text: <entity> 142 </entity> <entity type> monetaryItemType </entity type> <context> The Company has $ 142 million </context> | us-gaap:DebtInstrumentFaceAmount |
outpatient medical buildings that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> outpatient medical buildings that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments... | us-gaap:NumberOfInterestRateDerivativesHeld |
As of December 31, 2024, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were $ 18 million, which are recorded in other assets, net on the Consolidated Balance Sheets. | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, total unamortized debt issuance costs for the Revolving Facility and Commercial Paper Program were $ 18 million, which are recorded in other assets, net on the Consolidated Balance Sheets. </context> | us-gaap:UnamortizedDebtIssuanceExpense |
Effective interest rates on the senior unsecured notes range from 1.54 % to 6.87 % | text | 1.54 | percentItemType | text: <entity> 1.54 </entity> <entity type> percentItemType </entity type> <context> Effective interest rates on the senior unsecured notes range from 1.54 % to 6.87 % </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Effective interest rates on the senior unsecured notes range from 1.54 % to 6.87 % | text | 6.87 | percentItemType | text: <entity> 6.87 </entity> <entity type> percentItemType </entity type> <context> Effective interest rates on the senior unsecured notes range from 1.54 % to 6.87 % </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
with a weighted average effective interest rate of 3.96 % and a weighted average maturity of approximately 5 years. | text | 3.96 | percentItemType | text: <entity> 3.96 </entity> <entity type> percentItemType </entity type> <context> with a weighted average effective interest rate of 3.96 % and a weighted average maturity of approximately 5 years. </context> | us-gaap:DebtWeightedAverageInterestRate |
Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on c... | text | 3.44 | percentItemType | text: <entity> 3.44 </entity> <entity type> percentItemType </entity type> <context> Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of de... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on c... | text | 8.50 | percentItemType | text: <entity> 8.50 </entity> <entity type> percentItemType </entity type> <context> Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of de... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on c... | text | 5.16 | percentItemType | text: <entity> 5.16 </entity> <entity type> percentItemType </entity type> <context> Effective interest rates on the mortgage debt range from 3.44 % to 8.50 % with a weighted average effective interest rate of 5.16 % and a weighted average maturity of approximately 2 years. These interest rates include the impact of de... | us-gaap:DebtWeightedAverageInterestRate |
Additionally, the Company owns a 49 % interest in the Lab JV (see Note 9). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the cont... | text | 49 | percentItemType | text: <entity> 49 </entity> <entity type> percentItemType </entity type> <context> Additionally, the Company owns a 49 % interest in the Lab JV (see Note 9). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal a... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
On February 3, 2025, the Company’s Board of Directors declared a quarterly common stock cash dividend of $ 0.305 per share, reflecting an increase from $ 0.30 to $ 0.305 per share. The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025... | text | 0.305 | perShareItemType | text: <entity> 0.305 </entity> <entity type> perShareItemType </entity type> <context> On February 3, 2025, the Company’s Board of Directors declared a quarterly common stock cash dividend of $ 0.305 per share, reflecting an increase from $ 0.30 to $ 0.305 per share. The common stock cash dividend will be paid on Febru... | us-gaap:CommonStockDividendsPerShareDeclared |
On February 3, 2025, the Company’s Board of Directors declared a quarterly common stock cash dividend of $ 0.305 per share, reflecting an increase from $ 0.30 to $ 0.305 per share. The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025... | text | 0.30 | perShareItemType | text: <entity> 0.30 </entity> <entity type> perShareItemType </entity type> <context> On February 3, 2025, the Company’s Board of Directors declared a quarterly common stock cash dividend of $ 0.305 per share, reflecting an increase from $ 0.30 to $ 0.305 per share. The common stock cash dividend will be paid on Februa... | us-gaap:CommonStockDividendsPerShareDeclared |
Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) automatically converted into the right to receive 0.674 shares of the Company’s co... | text | 162 | sharesItemType | text: <entity> 162 </entity> <entity type> sharesItemType </entity type> <context> Pursuant to the terms set forth in the Merger Agreement, on the Closing Date, each outstanding share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement)... | us-gaap:StockIssuedDuringPeriodSharesAcquisitions |
During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $ 35.25 per share, after commissions. In December 2022, the Company settled all 9.1 ... | text | 9.1 | sharesItemType | text: <entity> 9.1 </entity> <entity type> sharesItemType </entity type> <context> During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $... | us-gaap:ForwardContractIndexedToIssuersEquityShares |
During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $ 35.25 per share, after commissions. In December 2022, the Company settled all 9.1 ... | text | 35.25 | perShareItemType | text: <entity> 35.25 </entity> <entity type> perShareItemType </entity type> <context> During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price ... | us-gaap:ForwardContractIndexedToIssuersEquityForwardRate |
During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $ 35.25 per share, after commissions. In December 2022, the Company settled all 9.1 ... | text | 34.01 | perShareItemType | text: <entity> 34.01 </entity> <entity type> perShareItemType </entity type> <context> During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price ... | us-gaap:ForwardContractIndexedToIssuersEquityForwardRate |
During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $ 35.25 per share, after commissions. In December 2022, the Company settled all 9.1 ... | text | 308 | monetaryItemType | text: <entity> 308 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2021, the Company utilized the forward provisions under the 2020 ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of... | us-gaap:StockIssuedDuringPeriodValueNewIssues |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 2.1 | sharesItemType | text: <entity> 2.1 </entity> <entity type> sharesItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Sha... | us-gaap:TreasuryStockSharesAcquired |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 27.16 | perShareItemType | text: <entity> 27.16 </entity> <entity type> perShareItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022... | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 56 | monetaryItemType | text: <entity> 56 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Sh... | us-gaap:TreasuryStockValueAcquiredCostMethod |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 10.5 | sharesItemType | text: <entity> 10.5 </entity> <entity type> sharesItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Sh... | us-gaap:TreasuryStockSharesAcquired |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 17.98 | perShareItemType | text: <entity> 17.98 </entity> <entity type> perShareItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022... | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 Share Repurchase Program”). Purchases of common stock under the 2022 Share Repurchase ... | text | 188 | monetaryItemType | text: <entity> 188 </entity> <entity type> monetaryItemType </entity type> <context> On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company could acquire shares of its common stock in the open market up to an aggregate purchase price of $ 500 million (the “2022 S... | us-gaap:TreasuryStockValueAcquiredCostMethod |
On July 24, 2024, the Company’s Board of Directors approved a new share repurchase program (the “2024 Share Repurchase Program”) to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Program, no further share repurchases may be made pursuant to the 2022 Share Repurchase ... | text | no | sharesItemType | text: <entity> no </entity> <entity type> sharesItemType </entity type> <context> On July 24, 2024, the Company’s Board of Directors approved a new share repurchase program (the “2024 Share Repurchase Program”) to supersede and replace the 2022 Share Repurchase Program. Upon adoption of the 2024 Share Repurchase Progra... | us-gaap:TreasuryStockSharesAcquired |
$ 500 million of the Company’s common stock remained available for repurchase under the 2024 Share Repurchase Program. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> $ 500 million of the Company’s common stock remained available for repurchase under the 2024 Share Repurchase Program. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In April 2024, the Company exercised its option to buy out four redeemable noncontrolling interests that met the criteria for redemption. Accordingly, during the year ended December 31, 2024, the Company made aggregate cash payments for the total redemption value of $ 53 million to the related noncontrolling interest h... | text | 53 | monetaryItemType | text: <entity> 53 </entity> <entity type> monetaryItemType </entity type> <context> In April 2024, the Company exercised its option to buy out four redeemable noncontrolling interests that met the criteria for redemption. Accordingly, during the year ended December 31, 2024, the Company made aggregate cash payments for... | us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue |
Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100 % owner of Healthpeak OP. Subsequent to the Reorganization, OP Unitholders were issued approximately 2 million OP Units during the year ended December 31, 2023, all of which were LTIP Units (as defined in Note 15).... | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100 % owner of Healthpeak OP. Subsequent to the Reorganization, OP Unitholders were issued approximately 2 million OP Units during the... | us-gaap:MinorityInterestOwnershipPercentageByParent |
shares of Healthpeak common stock are issuable upon conversion) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At December 31, 2024, the carrying value of the 11 million DownREIT units was $ 310 million. At December 31, 2023, there were ... | text | 310 | monetaryItemType | text: <entity> 310 </entity> <entity type> monetaryItemType </entity type> <context> shares of Healthpeak common stock are issuable upon conversion) outstanding in eight DownREIT LLCs, for all of which the Company holds a controlling interest and/or acts as the managing member. At December 31, 2024, the carrying value ... | us-gaap:MinorityInterestInPreferredUnitHolders |
On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, which was amended and restated in 2019 and further amended in 2023 (the “2014 Plan”... | text | no | sharesItemType | text: <entity> no </entity> <entity type> sharesItemType </entity type> <context> On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, w... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, which was amended and restated in 2019 and further amended in 2023 (the “2014 Plan”... | text | 31 | sharesItemType | text: <entity> 31 </entity> <entity type> sharesItemType </entity type> <context> On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, w... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, which was amended and restated in 2019 and further amended in 2023 (the “2014 Plan”... | text | 28 | sharesItemType | text: <entity> 28 </entity> <entity type> sharesItemType </entity type> <context> On May 11, 2006, the Company’s stockholders approved the 2006 Performance Incentive Plan, which was amended and restated in 2009 (the “2006 Plan”). On May 1, 2014, the Company’s stockholders approved the 2014 Performance Incentive Plan, w... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 26.0 | percentItemType | text: <entity> 26.0 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assump... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 33.0 | percentItemType | text: <entity> 33.0 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assump... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 38.9 | percentItemType | text: <entity> 38.9 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assump... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 5.2 | percentItemType | text: <entity> 5.2 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 4.4 | percentItemType | text: <entity> 4.4 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 3.5 | percentItemType | text: <entity> 3.5 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 4.5 | percentItemType | text: <entity> 4.5 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 4.4 | percentItemType | text: <entity> 4.4 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 1.8 | percentItemType | text: <entity> 1.8 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 10.0 | percentItemType | text: <entity> 10.0 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assump... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions |
0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumptions for awards granted during the years ended December 31, 2024, 2023, and 2022, re... | text | 5.8 | percentItemType | text: <entity> 5.8 </entity> <entity type> percentItemType </entity type> <context> 0 % to 200 % of target depending on the level of achievement of the performance criteria. The fair value of market-based restricted stock units is determined based on the Monte Carlo valuation model primarily using the following assumpt... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions |
Under the Plans, time-based LTIP Units and market-based LTIP Units (collectively, “LTIP Units”), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of three to six years . The fair value of the time-based LTIP Units is determined base... | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> Under the Plans, time-based LTIP Units and market-based LTIP Units (collectively, “LTIP Units”), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
Under the Plans, time-based LTIP Units and market-based LTIP Units (collectively, “LTIP Units”), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of three to six years . The fair value of the time-based LTIP Units is determined base... | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> Under the Plans, time-based LTIP Units and market-based LTIP Units (collectively, “LTIP Units”), are granted subject to certain restrictions. Time-based LTIP Units, which vest solely upon passage of time, generally vest over a period of ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
at December 31, 2024 and 0.2 million at December 31, 2023. There were no stock options exercised under the Plans for the years ended December 31, 2024, 2023, and 2022. No compensation cost related to stock options was incurred during the years ended December 31, 2024, 2023, and 2022. | text | 0.2 | sharesItemType | text: <entity> 0.2 </entity> <entity type> sharesItemType </entity type> <context> at December 31, 2024 and 0.2 million at December 31, 2023. There were no stock options exercised under the Plans for the years ended December 31, 2024, 2023, and 2022. No compensation cost related to stock options was incurred during the... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included $ 10 million of severance-related charges resulting from a decr... | text | 20 | monetaryItemType | text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended Decemb... | us-gaap:AllocatedShareBasedCompensationExpense |
Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included $ 10 million of severance-related charges resulting from a decr... | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended Decemb... | us-gaap:AllocatedShareBasedCompensationExpense |
Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included $ 10 million of severance-related charges resulting from a decr... | text | 32 | monetaryItemType | text: <entity> 32 </entity> <entity type> monetaryItemType </entity type> <context> Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended Decemb... | us-gaap:AllocatedShareBasedCompensationExpense |
Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included $ 10 million of severance-related charges resulting from a decr... | text | 10 | monetaryItemType | text: <entity> 10 </entity> <entity type> monetaryItemType </entity type> <context> Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended Decemb... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost |
Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended December 31, 2022 included $ 10 million of severance-related charges resulting from a decr... | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> Total stock-based compensation cost was $ 20 million, $ 19 million, and $ 32 million for the years ended December 31, 2024, 2023, and 2022, respectively, which was recognized in general and administrative expenses. The year ended Decemb... | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
$ 4 million and $ 8 million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> $ 4 million and $ 8 million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets. </context> | us-gaap:SeveranceCosts1 |
$ 4 million and $ 8 million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> $ 4 million and $ 8 million of these severance-related charges have not yet been paid and were included in accounts payable, accrued liabilities, and other liabilities on the Consolidated Balance Sheets. </context> | us-gaap:SeveranceCosts1 |
At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, 2023, goodwill of $ 18 million was allocated to the Company’s segment assets as fol... | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31,... | us-gaap:Goodwill |
At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, 2023, goodwill of $ 18 million was allocated to the Company’s segment assets as fol... | text | 65 | monetaryItemType | text: <entity> 65 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31,... | us-gaap:Goodwill |
At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, 2023, goodwill of $ 18 million was allocated to the Company’s segment assets as fol... | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, ... | us-gaap:Goodwill |
At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, 2023, goodwill of $ 18 million was allocated to the Company’s segment assets as fol... | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31,... | us-gaap:Goodwill |
At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31, 2023, goodwill of $ 18 million was allocated to the Company’s segment assets as fol... | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, goodwill of $ 69 million was allocated to the Company’s segment assets as follows: (i) $ 65 million for outpatient medical, (ii) $ 2 million for CCRC, and (iii) $ 2 million for other non-reportable. At December 31,... | us-gaap:Goodwill |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 272 | monetaryItemType | text: <entity> 272 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 325 | monetaryItemType | text: <entity> 325 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 509 | monetaryItemType | text: <entity> 509 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 217 | monetaryItemType | text: <entity> 217 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 318 | monetaryItemType | text: <entity> 318 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 527 | monetaryItemType | text: <entity> 527 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mil... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 55 | monetaryItemType | text: <entity> 55 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mill... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 milli... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 million was attributable to the REIT entities for the years then ended. The TRS entities... | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s pretax income (loss) from continuing operations for the years ended December 31, 2024, 2023, and 2022 was $ 272 million, $ 325 million, and $ 509 million, respectively, of which $ 217 million, $ 318 million, and $ 527 mill... | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
The Company’s income tax benefit from discontinued operations was zero , zero , and $ 0.3 million for the years ended December 31, 2024, 2023, and 2022, respectively (see Note 5). | text | zero | monetaryItemType | text: <entity> zero </entity> <entity type> monetaryItemType </entity type> <context> The Company’s income tax benefit from discontinued operations was zero , zero , and $ 0.3 million for the years ended December 31, 2024, 2023, and 2022, respectively (see Note 5). </context> | us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation |
The Company’s income tax benefit from discontinued operations was zero , zero , and $ 0.3 million for the years ended December 31, 2024, 2023, and 2022, respectively (see Note 5). | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s income tax benefit from discontinued operations was zero , zero , and $ 0.3 million for the years ended December 31, 2024, 2023, and 2022, respectively (see Note 5). </context> | us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company ... | us-gaap:IncomeTaxExpenseBenefit |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company ... | us-gaap:IncomeTaxExpenseBenefit |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company ... | us-gaap:IncomeTaxExpenseBenefit |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company c... | us-gaap:DeferredIncomeTaxesAndTaxCredits |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company ... | us-gaap:DeferredIncomeTaxesAndTaxCredits |
As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company concluded that it was more likely than not that certain deferred tax assets (primari... | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2022, the Company recorded a valuation allowance against certain SHOP deferred tax assets generated by net operating losses (“NOLs”) of its TRS entities. During the years ended December 31, 2024 and 2023, the Company ... | us-gaap:DeferredIncomeTaxesAndTaxCredits |
At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. | text | 193 | monetaryItemType | text: <entity> 193 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. </c... | us-gaap:DeferredTaxAssetsOperatingLossCarryforwards |
At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. </con... | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration |
At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. | text | 191 | monetaryItemType | text: <entity> 191 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the Company had a NOL carryforward of $ 193 million related to the TRS entities. If unused, $ 2 million will begin to expire in 2035. The remainder, totaling $ 191 million, may be carried forward indefinitely. </c... | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration |
In December 2021, the Company acquired a 38 % interest in a lab development joint venture in Needham, Massachusetts for $ 13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations... | text | 38 | percentItemType | text: <entity> 38 </entity> <entity type> percentItemType </entity type> <context> In December 2021, the Company acquired a 38 % interest in a lab development joint venture in Needham, Massachusetts for $ 13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liab... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In December 2021, the Company acquired a 38 % interest in a lab development joint venture in Needham, Massachusetts for $ 13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations... | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> In December 2021, the Company acquired a 38 % interest in a lab development joint venture in Needham, Massachusetts for $ 13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and lia... | us-gaap:PaymentsToAcquireEquityMethodInvestments |
At December 31, 2022, the Company held $ 22 million | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2022, the Company held $ 22 million </context> | us-gaap:DebtSecurities |
. The Company holds a 51 % ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases outpatient medical buildings (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the manage... | text | 51 | percentItemType | text: <entity> 51 </entity> <entity type> percentItemType </entity type> <context> . The Company holds a 51 % ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases outpatient medical buildings (“Ventures V”). The Company classifies Ventures V as a VIE du... | us-gaap:VariableInterestEntityOwnershipPercentage |
. The Company holds a 51 % ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases outpatient medical buildings (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint ... | text | 51 | percentItemType | text: <entity> 51 </entity> <entity type> percentItemType </entity type> <context> . The Company holds a 51 % ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases outpatient medical buildings (the “MSREI JV”). The MSREI JV is a VIE due to the non-manag... | us-gaap:VariableInterestEntityOwnershipPercentage |
. At December 31, 2023, the Company held a 98 % or greater ownership interest in multiple joint venture entities that owned and leased lab buildings (the “Lab JVs”). The Lab JVs were VIEs as the members shared in certain decisions of the entities, but substantially all of the activities were performed on behalf of the... | text | 98 | percentItemType | text: <entity> 98 </entity> <entity type> percentItemType </entity type> <context> . At December 31, 2023, the Company held a 98 % or greater ownership interest in multiple joint venture entities that owned and leased lab buildings (the “Lab JVs”). The Lab JVs were VIEs as the members shared in certain decisions of th... | us-gaap:VariableInterestEntityOwnershipPercentage |
The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates and their related potential im... | text | 53 | monetaryItemType | text: <entity> 53 </entity> <entity type> monetaryItemType </entity type> <context> The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company... | us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions |
During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designa... | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate c... | us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions |
During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designa... | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate ... | us-gaap:NumberOfInterestRateDerivativesHeld |
During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designa... | text | 142 | monetaryItemType | text: <entity> 142 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company recognized a $ 2 million increase in the fair value of its interest rate cap instruments within other income (expense), net. In April 2022, the Company terminated these interest rate... | us-gaap:DerivativeNotionalAmount |
In August 2022, the Company entered into two forward-starting interest rate swap instruments on the $ 500 million aggregate principal amount of the 2027 Term Loans (see Note 11). The interest rate swap instruments are designated as cash flow hedges. | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments on the $ 500 million aggregate principal amount of the 2027 Term Loans (see Note 11). The interest rate swap instruments are designated as cash... | us-gaap:NumberOfInterestRateDerivativesHeld |
In August 2022, the Company entered into two forward-starting interest rate swap instruments on the $ 500 million aggregate principal amount of the 2027 Term Loans (see Note 11). The interest rate swap instruments are designated as cash flow hedges. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> In August 2022, the Company entered into two forward-starting interest rate swap instruments on the $ 500 million aggregate principal amount of the 2027 Term Loans (see Note 11). The interest rate swap instruments are designated as cas... | us-gaap:DerivativeNotionalAmount |
In January 2024, the Company entered into forward-starting interest rate swap instruments on the $ 750 million aggregate principal amount of the 2029 Term Loan (see Note 11). The interest rate swap instruments are designated as cash flow hedges. | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, the Company entered into forward-starting interest rate swap instruments on the $ 750 million aggregate principal amount of the 2029 Term Loan (see Note 11). The interest rate swap instruments are designated as cash fl... | us-gaap:DerivativeAssetNotionalAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on $ 36 million of var... | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated... | us-gaap:NumberOfInterestRateDerivativesHeld |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on $ 36 million of var... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated ... | us-gaap:DerivativeAssetNotionalAmount |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on $ 36 million of var... | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated a... | us-gaap:NumberOfInterestRateDerivativesHeld |
Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated as cash flow hedges and (ii) one interest rate swap instrument on $ 36 million of var... | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> Additionally, on March 1, 2024, concurrently with the consummation of the Merger, the Company acquired: (i) three interest rate swap instruments on the $ 400 million aggregate principal amount of the 2028 Term Loan that are designated a... | us-gaap:DebtInstrumentFaceAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.